Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Different signalling pathways regulate VEGF and IL-8 expression in breast cancer: implications for therapy.

Dina Chelouche-Lev1, Claudia P Miller, Carmen Tellez

  • 1Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 173, Houston, TX 77030, USA.

European Journal of Cancer (Oxford, England : 1990)
|November 3, 2004
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FDA Approval Summary: Tarlatamab for the Treatment of Extensive-Stage Small Cell Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

FDA Approval Summary: Vorasidenib for IDH-Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations.

The oncologist·2024
Same author

US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality Therapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024

In breast cancer, inhibiting specific signaling pathways like MAPK and PI3K can reduce pro-angiogenic cytokines vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8). Targeting the dominant pathway may offer effective anti-angiogenic therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Elevated pro-angiogenic cytokines, including vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8), correlate with aggressive breast cancer and poor patient survival.
  • VEGF and IL-8 are often co-expressed in breast cancer cell lines, suggesting a link to tumor angiogenesis.

Purpose of the Study:

  • To investigate the effects of inhibiting mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K) signaling pathways on VEGF and IL-8 expression in breast cancer cell lines.
  • To determine if targeting specific signaling pathways can downregulate key angiogenic cytokines involved in breast cancer progression.

Main Methods:

  • Utilized four distinct breast cancer cell lines with varying expression levels of VEGF and IL-8.
  • Administered specific inhibitors: U0126 (a MEK inhibitor targeting MAPK) and LY294002 (a PI3K inhibitor).

Related Experiment Videos

  • Quantified the changes in VEGF and IL-8 expression following inhibitor treatments.

    • Main Results:

    • The MEK inhibitor U0126 effectively reduced VEGF and IL-8 in MDA-MB-231 cells, with partial effects in MDA-MB-468 and Hs578T cells, and minimal impact on GI101A cells.
    • The PI3K inhibitor LY294002 demonstrated efficacy in GI101A and MDA-MB-468 cells, with partial reduction in Hs578T and less effect in MDA-MB-231 cells.
    • Indicated that VEGF and IL-8 are regulated by distinct signaling pathways in a cell-line-specific manner.

    Conclusions:

    • Interleukin-8 (IL-8) and vascular endothelial growth factor (VEGF) expression are differentially regulated by MAPK and PI3K pathways across breast cancer cell lines.
    • Inhibition of the predominant active signaling pathway can lead to downregulation of both IL-8 and VEGF.
    • Identifying the active signaling pathway in individual tumors may reveal specific targets for developing novel anti-angiogenic therapies for breast cancer.